191 related articles for article (PubMed ID: 38273401)
1. Blood FOLR3 methylation dysregulations and heterogeneity in non-small lung cancer highlight its strong associations with lung squamous carcinoma.
Qu Y; Zhang X; Qiao R; Di F; Song Y; Wang J; Ji L; Zhang J; Gu W; Fang Y; Han B; Yang R; Dai L; Ouyang S
Respir Res; 2024 Jan; 25(1):59. PubMed ID: 38273401
[TBL] [Abstract][Full Text] [Related]
2. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
Yang K; Wu Y
BMC Cancer; 2021 Feb; 21(1):128. PubMed ID: 33549049
[TBL] [Abstract][Full Text] [Related]
3. Differential
Lin S; Tian C; Li J; Liu B; Ma T; Chen K; Gong W; Wang JM; Huang J
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33786615
[TBL] [Abstract][Full Text] [Related]
4. Identification of diagnostic DNA methylation biomarkers specific for early-stage lung adenocarcinoma.
Cai Q; Zhang P; He B; Zhao Z; Zhang Y; Peng X; Xie H; Wang X
Cancer Genet; 2020 Aug; 246-247():1-11. PubMed ID: 32805686
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic-smoking interaction reveals histologically heterogeneous effects of TRIM27 DNA methylation on overall survival among early-stage NSCLC patients.
Ji X; Lin L; Shen S; Dong X; Chen C; Li Y; Zhu Y; Huang H; Chen J; Chen X; Wei L; He J; Duan W; Su L; Jiang Y; Fan J; Guan J; You D; Shafer A; Bjaanaes MM; Karlsson A; Planck M; Staaf J; Helland Å; Esteller M; Wei Y; Zhang R; Chen F; Christiani DC
Mol Oncol; 2020 Nov; 14(11):2759-2774. PubMed ID: 33448640
[TBL] [Abstract][Full Text] [Related]
6. Association of TOP2A and ADH1B with lipid levels and prognosis in patients with lung adenocarcinoma and squamous cell carcinoma.
Yin D; Zhang Y; Li H; Cheng L
Clin Respir J; 2023 Dec; 17(12):1301-1315. PubMed ID: 37985446
[TBL] [Abstract][Full Text] [Related]
7. Bioinformatics analysis of differentially expressed miRNAs in non-small cell lung cancer.
Yu H; Pang Z; Li G; Gu T
J Clin Lab Anal; 2021 Feb; 35(2):e23588. PubMed ID: 32965722
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
Gan BL; He RQ; Zhang Y; Wei DM; Hu XH; Chen G
Int J Oncol; 2018 Oct; 53(4):1557-1579. PubMed ID: 30066858
[TBL] [Abstract][Full Text] [Related]
9. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
Yang Y; Wang M; Liu B
J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
[TBL] [Abstract][Full Text] [Related]
10. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
Hou G; Lu Z; Bi Y; Deng J; Yang X
Med Oncol; 2022 Feb; 39(5):51. PubMed ID: 35150321
[TBL] [Abstract][Full Text] [Related]
11. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
Xu XL; Gong Y; Zhao DP
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
[TBL] [Abstract][Full Text] [Related]
12. System analysis of
Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
[TBL] [Abstract][Full Text] [Related]
13. Novel blood-based FUT7 DNA methylation is associated with lung cancer: especially for lung squamous cell carcinoma.
Fang Y; Qu Y; Ji L; Sun H; Li J; Zhao Y; Liang F; Wang Z; Su J; Liu J; Dai L; Ouyang S
Clin Epigenetics; 2022 Dec; 14(1):167. PubMed ID: 36463240
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic loss of putative tumor suppressor SFRP3 correlates with poor prognosis of lung adenocarcinoma patients.
Schlensog M; Magnus L; Heide T; Eschenbruch J; Steib F; Tator M; Kloten V; Rose M; Noetzel E; Gaisa NT; Knüchel R; Dahl E
Epigenetics; 2018; 13(3):214-227. PubMed ID: 27623992
[TBL] [Abstract][Full Text] [Related]
15. Expression and Clinical Significance of lncRNA OSER1-AS1 in Peripheral Blood of Patients with Non-Small Cell Lung Cancer.
Chen P; Qin Z; Sun X; Yang J; Lv J; Diao M
Cells Tissues Organs; 2022; 211(5):589-600. PubMed ID: 34525476
[TBL] [Abstract][Full Text] [Related]
16. The increased expression and aberrant methylation of SHC1 in non-small cell lung cancer: Integrative analysis of clinical and bioinformatics databases.
Liang Y; Lei Y; Du M; Liang M; Liu Z; Li X; Gao Y
J Cell Mol Med; 2021 Jul; 25(14):7039-7051. PubMed ID: 34117717
[TBL] [Abstract][Full Text] [Related]
17. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Li Y; Zheng P; Zhan X
Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
[TBL] [Abstract][Full Text] [Related]
18. [Identification of differentially expressed genes between lung adenocarcinoma and squamous cell carcinoma using transcriber signature analysis].
Peng S; Li X; Liu Q; Zhang Y; Zou L; Gong X; Wang M; Ma X
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Jun; 39(6):641-649. PubMed ID: 31270041
[TBL] [Abstract][Full Text] [Related]
19.
Zhang W; Li T; Hu B; Li H
Technol Cancer Res Treat; 2020; 19():1533033820957030. PubMed ID: 33084541
[TBL] [Abstract][Full Text] [Related]
20. What's the difference between lung adenocarcinoma and lung squamous cell carcinoma? Evidence from a retrospective analysis in a cohort of Chinese patients.
Wang W; Liu H; Li G
Front Endocrinol (Lausanne); 2022; 13():947443. PubMed ID: 36105402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
